Other research analysts also recently issued reports about the company. BidaskClub upgraded NantHealth from a strong sell rating to a sell rating in a research note on Tuesday, January 9th. Zacks Investment Research upgraded NantHealth from a hold rating to a buy rating and set a $4.25 target price on the stock in a research note on Thursday, January 11th. Finally, Cowen reiterated a buy rating and issued a $4.50 target price on shares of NantHealth in a research note on Tuesday, March 20th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $7.46.
NH stock opened at $3.12 on Wednesday. NantHealth has a 12-month low of $2.60 and a 12-month high of $5.70. The company has a market capitalization of $344.20, a P/E ratio of -2.09 and a beta of 0.64. The company has a debt-to-equity ratio of 1.01, a quick ratio of 2.36 and a current ratio of 2.28.
Institutional investors have recently bought and sold shares of the stock. Teachers Advisors LLC boosted its stake in shares of NantHealth by 351.8% in the second quarter. Teachers Advisors LLC now owns 31,578 shares of the company’s stock valued at $134,000 after buying an additional 24,588 shares in the last quarter. California State Teachers Retirement System boosted its stake in shares of NantHealth by 132.4% in the second quarter. California State Teachers Retirement System now owns 31,600 shares of the company’s stock valued at $134,000 after buying an additional 18,000 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of NantHealth in the fourth quarter valued at approximately $103,000. Schwab Charles Investment Management Inc. purchased a new stake in shares of NantHealth in the third quarter valued at approximately $180,000. Finally, Deutsche Bank AG boosted its stake in shares of NantHealth by 117.4% in the fourth quarter. Deutsche Bank AG now owns 45,610 shares of the company’s stock valued at $137,000 after buying an additional 24,635 shares in the last quarter. Hedge funds and other institutional investors own 6.27% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “NantHealth (NH) Given a $5.00 Price Target at Jefferies Group” was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3298288/nanthealth-nh-given-a-5-00-price-target-at-jefferies-group.html.
NantHealth Company Profile
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.